[1]
Burch R,Rizzoli P,Loder E, The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache. 2018 Apr
[PubMed PMID: 29527677]
[2]
Tabatabai RR,Swadron SP, Headache in the Emergency Department: Avoiding Misdiagnosis of Dangerous Secondary Causes. Emergency medicine clinics of North America. 2016 Nov
[PubMed PMID: 27741984]
[3]
Potter R,Probyn K,Bernstein C,Pincus T,Underwood M,Matharu M, Diagnostic and classification tools for chronic headache disorders: A systematic review. Cephalalgia : an international journal of headache. 2019 May
[PubMed PMID: 30335472]
Level 1 (high-level) evidence
[4]
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia : an international journal of headache. 2018 Jan
[PubMed PMID: 29368949]
[6]
Rasmussen BK,Jensen R,Schroll M,Olesen J, Epidemiology of headache in a general population--a prevalence study. Journal of clinical epidemiology. 1991
[PubMed PMID: 1941010]
[8]
Gaul C,Meßlinger K,Holle-Lee D,Neeb L, [Pathophysiology of Headaches]. Deutsche medizinische Wochenschrift (1946). 2017 Mar
[PubMed PMID: 28329901]
[9]
Godwin SA,Cherkas DS,Panagos PD,Shih RD,Byyny R,Wolf SJ, Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Headache Annals of emergency medicine. 2019 Oct
[PubMed PMID: 31543134]
[10]
Clinical policy: critical issues in the evaluation and management of patients presenting to the emergency department with acute headache. Annals of emergency medicine. 2002 Jan
[PubMed PMID: 11782746]
[12]
Venkatesan A, Case 13: a man with progressive headache and confusion. MedGenMed : Medscape general medicine. 2006 Jul 27
[PubMed PMID: 17406159]
Level 3 (low-level) evidence
[14]
Long D,Koyfman A,Long B, The Thunderclap Headache: Approach and Management in the Emergency Department. The Journal of emergency medicine. 2019 Jun
[PubMed PMID: 30879843]
[15]
Carpenter CR,Hussain AM,Ward MJ,Zipfel GJ,Fowler S,Pines JM,Sivilotti ML, Spontaneous Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis Describing the Diagnostic Accuracy of History, Physical Examination, Imaging, and Lumbar Puncture With an Exploration of Test Thresholds. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016 Sep
[PubMed PMID: 27306497]
Level 1 (high-level) evidence
[16]
Filler L,Akhter M,Nimlos P, Evaluation and Management of the Emergency Department Headache. Seminars in neurology. 2019 Feb
[PubMed PMID: 30743289]
[18]
Runchey S,McGee S, Does this patient have a hemorrhagic stroke?: clinical findings distinguishing hemorrhagic stroke from ischemic stroke. JAMA. 2010 Jun 9
[PubMed PMID: 20530782]
[19]
Tan MG,Worley B,Kim WB,Ten Hove M,Beecker J, Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes. American journal of clinical dermatology. 2020 Apr
[PubMed PMID: 31741184]
Level 1 (high-level) evidence
[20]
Wakerley BR,Tan MH,Ting EY, Idiopathic intracranial hypertension. Cephalalgia : an international journal of headache. 2015 Mar
[PubMed PMID: 24847166]
[21]
Adebayo O,Rogers RL, Hypertensive Emergencies in the Emergency Department. Emergency medicine clinics of North America. 2015 Aug
[PubMed PMID: 26226865]
[23]
M S,Lamont AC,Alias NA,Win MN, Red flags in patients presenting with headache: clinical indications for neuroimaging. The British journal of radiology. 2003 Aug
[PubMed PMID: 12893694]
[24]
Parikh M,Miller NR,Lee AG,Savino PJ,Vacarezza MN,Cornblath W,Eggenberger E,Antonio-Santos A,Golnik K,Kardon R,Wall M, Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006 Oct
[PubMed PMID: 16884778]
[25]
Kermani TA,Schmidt J,Crowson CS,Ytterberg SR,Hunder GG,Matteson EL,Warrington KJ, Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Seminars in arthritis and rheumatism. 2012 Jun
[PubMed PMID: 22119103]
[26]
Alons IM,Jellema K,Wermer MJ,Algra A, D-dimer for the exclusion of cerebral venous thrombosis: a meta-analysis of low risk patients with isolated headache. BMC neurology. 2015 Jul 28
[PubMed PMID: 26215857]
Level 1 (high-level) evidence
[27]
Smith E,Kumar V, BET 1: Does a normal D-dimer rule out cerebral venous sinus thrombosis (CVST)? Emergency medicine journal : EMJ. 2018 Jun
[PubMed PMID: 29784833]
[28]
Saposnik G,Barinagarrementeria F,Brown RD Jr,Bushnell CD,Cucchiara B,Cushman M,deVeber G,Ferro JM,Tsai FY, Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Apr
[PubMed PMID: 21293023]
[29]
Blok KM,Rinkel GJ,Majoie CB,Hendrikse J,Braaksma M,Tijssen CC,Wong YY,Hofmeijer J,Extercatte J,Kerklaan B,Schreuder TH,ten Holter S,Verheul F,Harlaar L,Pruissen DM,Kwa VI,Brouwers PJ,Remmers MJ,Schonewille WJ,Kruyt ND,Vergouwen MD, CT within 6 hours of headache onset to rule out subarachnoid hemorrhage in nonacademic hospitals. Neurology. 2015 May 12
[PubMed PMID: 25862794]
[30]
Long BJ,Koyfman A, Benign Headache Management in the Emergency Department. The Journal of emergency medicine. 2018 Apr
[PubMed PMID: 29395690]
[31]
Levin M, Approach to the Workup and Management of Headache in the Emergency Department and Inpatient Settings. Seminars in neurology. 2015 Dec
[PubMed PMID: 26595867]
[32]
Kelley NE,Tepper DE, Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012 Mar
[PubMed PMID: 22404708]
[33]
Friedman BW,Greenwald P,Bania TC,Esses D,Hochberg M,Solorzano C,Corbo J,Chu J,Chew E,Cheung P,Fearon S,Paternoster J,Baccellieri A,Clark S,Bijur PE,Lipton RB,Gallagher EJ, Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007 Nov 27
[PubMed PMID: 17942818]
Level 1 (high-level) evidence
[34]
Latev A,Friedman BW,Irizarry E,Solorzano C,Restivo A,Chertoff A,Zias E,Gallagher EJ, A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department. Annals of emergency medicine. 2019 Feb
[PubMed PMID: 30449536]
Level 1 (high-level) evidence
[36]
Schaffer JT,Hunter BR,Ball KM,Weaver CS, Noninvasive sphenopalatine ganglion block for acute headache in the emergency department: a randomized placebo-controlled trial. Annals of emergency medicine. 2015 May
[PubMed PMID: 25577713]
Level 1 (high-level) evidence
[37]
Binfalah M,Alghawi E,Shosha E,Alhilly A,Bakhiet M, Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache. Pain research and treatment. 2018
[PubMed PMID: 29862074]
[38]
Zobdeh F, Eremenko II, Akan MA, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review. Pharmaceutics. 2022 Jun 1:14(6):. doi: 10.3390/pharmaceutics14061190. Epub 2022 Jun 1
[PubMed PMID: 35745763]
Level 1 (high-level) evidence
[39]
Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. The American journal of medicine. 2020 Apr:133(4):412-416. doi: 10.1016/j.amjmed.2019.10.023. Epub 2019 Nov 9
[PubMed PMID: 31712099]
[40]
Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 Jan:60(1):58-70. doi: 10.1111/head.13663. Epub 2019 Oct 24
[PubMed PMID: 31647577]
Level 1 (high-level) evidence
[41]
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan:55(1):3-20. doi: 10.1111/head.12499. Epub
[PubMed PMID: 25600718]
[42]
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane database of systematic reviews. 2014 May 28:2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2. Epub 2014 May 28
[PubMed PMID: 24865446]
Level 3 (low-level) evidence
[43]
Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The journal of headache and pain. 2017 Dec:18(1):17. doi: 10.1186/s10194-016-0717-7. Epub 2017 Feb 7
[PubMed PMID: 28176235]
Level 1 (high-level) evidence
[44]
Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clinical therapeutics. 2000 Aug:22(8):970-80
[PubMed PMID: 10972633]
[45]
Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. The Cochrane database of systematic reviews. 2014 May 21:2014(5):CD008616. doi: 10.1002/14651858.CD008616.pub2. Epub 2014 May 21
[PubMed PMID: 24848613]
Level 1 (high-level) evidence
[46]
Oldman AD, Smith LA, McQuay HJ, Moore AR. Pharmacological treatments for acute migraine: quantitative systematic review. Pain. 2002 Jun:97(3):247-257. doi: 10.1016/S0304-3959(02)00024-6. Epub
[PubMed PMID: 12044621]
Level 1 (high-level) evidence
[47]
. Eletriptan (relpax) for migraine. The Medical letter on drugs and therapeutics. 2003 Apr 28:45(1155):33-4
[PubMed PMID: 12719695]
Level 3 (low-level) evidence
[48]
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb:52(2):292-306. doi: 10.1111/j.1526-4610.2011.02070.x. Epub
[PubMed PMID: 22309235]
[49]
Lipton RB,Croop R,Stock EG,Stock DA,Morris BA,Frost M,Dubowchik GM,Conway CM,Coric V,Goadsby PJ, Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. The New England journal of medicine. 2019 Jul 11
[PubMed PMID: 31291516]
[50]
Dodick DW,Lipton RB,Ailani J,Lu K,Finnegan M,Trugman JM,Szegedi A, Ubrogepant for the Treatment of Migraine. The New England journal of medicine. 2019 Dec 5
[PubMed PMID: 31800988]
[51]
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15:325(23):2357-2369. doi: 10.1001/jama.2021.7939. Epub
[PubMed PMID: 34128998]
Level 1 (high-level) evidence
[52]
Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clinic proceedings. 1996 Nov:71(11):1055-66
[PubMed PMID: 8917290]
Level 3 (low-level) evidence
[53]
Obermann M, Holle D, Naegel S, Burmeister J, Diener HC. Pharmacotherapy options for cluster headache. Expert opinion on pharmacotherapy. 2015 Jun:16(8):1177-84. doi: 10.1517/14656566.2015.1040392. Epub 2015 Apr 24
[PubMed PMID: 25911317]
Level 3 (low-level) evidence
[54]
Lanteri-Minet M, Silhol F, Piano V, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day). The journal of headache and pain. 2011 Apr:12(2):173-6. doi: 10.1007/s10194-010-0289-x. Epub 2011 Jan 22
[PubMed PMID: 21258839]
[55]
Gaul C, Roguski J, Dresler T, Abbas H, Totzeck A, Görlinger K, Diener HC, Weber R. Efficacy and safety of a single occipital nerve blockade in episodic and chronic cluster headache: A prospective observational study. Cephalalgia : an international journal of headache. 2017 Aug:37(9):873-880. doi: 10.1177/0333102416654886. Epub 2016 Jun 16
[PubMed PMID: 27313215]
Level 2 (mid-level) evidence
[56]
Murinova N,Krashin D, Chronic daily headache. Physical medicine and rehabilitation clinics of North America. 2015 May
[PubMed PMID: 25952071]
[57]
Jay GW,Barkin RL, Primary Headache Disorders- Part 2: Tension-type headache and medication overuse headache. Disease-a-month : DM. 2017 Dec
[PubMed PMID: 28886861]
[58]
Alstadhaug KB,Andreou AP, Caffeine and Primary (Migraine) Headaches-Friend or Foe? Frontiers in neurology. 2019
[PubMed PMID: 31849829]
[59]
Ferini-Strambi L,Galbiati A,Combi R, Sleep disorder-related headaches. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2019 May
[PubMed PMID: 30906963]
[60]
Klenofsky B,Pace A,Natbony LR,Sheikh HU, Episodic Migraine Comorbidities: Avoiding Pitfalls and Taking Therapeutic Opportunities. Current pain and headache reports. 2019 Jan 12
[PubMed PMID: 30637489]
[61]
Allen D,Gillen E,Rixson L, The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review. JBI library of systematic reviews. 2009
[PubMed PMID: 27820426]
Level 1 (high-level) evidence